Testing estimates of year-to-year variation in global net primary production (NPP) poses some challenges. Large-scale, multiyear records of production are not readily available for natural systems but are for agricultural systems. We use records of agricultural yields at selected sites to test NPP estimates produced by CASA, a global-scale production model driven by both meteorological data and the satellite-derived normalized difference vegetation index (NDVI). We also test estimates produced by the Miami model, which has underlain several analyses of biosphere response to interannual changes in climate. In addition, we test estimates against tree ring data for one boreal site for which data from both coniferous and deciduous species were available. The agricultural tests demonstrate that CASA can reasonably estimate interannual variation in production. The Miami model estimates variation more poorly. However, differences in NDVI-processing algorithms substantially affect CASA's estimates of interannual variation. Of the four versions tested, the FASIR NDVI most closely reproduced yield data and showed the least correlation with changes in equatorial crossing time of the National Oceanic and Atmospheric Administration satellites. One issue raised is the source of the positive trends evident in CASA's NDVI-based estimates of global NPP. The existence of these trends is consistent with potential stimulation of terrestrial production by factors such as CO₂ enrichment, N fertilization, or temperature warming, but the magnitude of the global trends seen is significantly greater than suggested by constraints imposed by atmospheric fluxes.

A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients' lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter methylation events involving 168 genes. Analyses delineated four ovarian cancer transcriptional subtypes, three microRNA subtypes, four promoter methylation subtypes and a transcriptional signature associated with survival duration, and shed new light on the impact that tumours with BRCA1/2 (BRCA1 or BRCA2) and CCNE1 aberrations have on survival. Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed, and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology.